Our Library

Product Correction for Invega Sustenna®, Invega Trinza®, Invega Hafyera®

DrugAlert Volume 1088

HPS Pharmacies wish to advise that Janssen-Cilag, in consultation with the Therapeutic Goods Administration (TGA), has issued a product correction for all strenghts of Invega Sustenna®, Invega Trinza®, Invega Hafyera® pre-filled syringes, as follows:…

Read more

Availability of Creon®

DrugAlert Volume 1087

HPS Pharmacies wish to advise that Viatris is experiencing a supply interruption for Creon® capsules, as follows: Creon® 25,000 Pancreatic extract 300 mg ARTG 158452  Creon® 35,000 Pancreatic extract 420 mg ARTG 313833  Supplies…

Read more

Updated Guidelines on Vasomotor and Genitourinary Symptoms of Menopause

The Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG) has recently published its Management of Vasomotor and Genitourinary Symptoms of Menopause (C-Gyn 9) guideline. This document is intended to support the…

Read more

Drug Recall for Flumazenil-Baxter

DrugAlert Volume 1086

HPS Pharmacies wish to advise that Baxter Healthcare, in consultation with the Therapeutic Goods Administration (TGA), has issued a drug recall of the following product: Flumazenil-Baxter Ampoules Flumazenil 0.5 mg/5 mL ARTG 231405 This…

Read more

Deucravacitinib for Psoriatic Arthritis

Drugline Volume 560

Deucravacitinib has recently been approved for the treatment of adults with active psoriatic arthritis, expanding its therapeutic role beyond plaque psoriasis. Psoriatic arthritis is a chronic, autoimmune condition associated with psoriasis of the skin…

Read more
prescription

Deucravacitinib for Psoriatic Arthritis

Drugline Volume 560

Deucravacitinib has recently been approved for the treatment of adults with active psoriatic arthritis, expanding its therapeutic role beyond plaque psoriasis. Psoriatic arthritis is a chronic, autoimmune condition associated with psoriasis of the skin…

Read more
Load More

November 2020

February 2020

Xerostomia (Feb. 27 2020)

Availability of Glucose Intravenous Infusion (Feb. 26 2020)

Availability of Ephedrine Hydrochloride (Feb. 26 2020)

Availability of OsmoLax® (Feb. 26 2020)

Availability of Famotidine (Feb. 26 2020)

Availability of BenPen™ (Feb. 21 2020)

Availability of Carbimazole (Feb. 21 2020)

Availability of Calcium Gluconate Gel (Feb. 21 2020)

Availability of Pindolol (Feb. 21 2020)

Availability of Bleomycin Vials (Feb. 21 2020)

Non-Steroidal Topical Therapy for Dermatitis (Feb. 20 2020)

Availability of Prazosin (Feb. 20 2020)

Availability of Phenoxymethylpenicillin (Feb. 20 2020)

Availability of Dantrolene (Feb. 20 2020)

Availability of Minipress® (Feb. 20 2020)

Availability of Verapamil Tablets (Feb. 19 2020)

Availability of Carafate® Tablets (Feb. 19 2020)

Availability of Pneumovax® 23 (Feb. 18 2020)

Availability of Span-K® Tablets (Feb. 17 2020)

Availability of Irinotecan (Feb. 17 2020)

Defect correction for Palexia® SR 100mg (Feb. 14 2020)

Availability of Haemorol™ (Feb. 14 2020)

Availability of Primacin® (Feb. 14 2020)

Availability of EpiPen® Jr. (Feb. 14 2020)

Monoclonal Antibodies for Migraine (Feb. 13 2020)

Availability of Amoxicillin & Clavulanic Acid Suspension (Feb. 12 2020)

Availability of Emollient Ointment Sterile (Feb. 11 2020)

Availability of Hydroxocobalamin Ampoules (Feb. 11 2020)

Availability of Fleet® Ready-to-Use Enema (Feb. 07 2020)

Availability of Gentamicin Ampoules (Feb. 07 2020)

Availability of Hand Sanitisers (Feb. 07 2020)

Availability of Ciprofloxacin IV (Feb. 07 2020)

Updated PBS-listing for Pembrolizumab in treatment of metastatic non-small cell lung cancer (Feb. 07 2020)

Availability of Zyban® SR Tablets (Feb. 06 2020)

Availability of DBL™ Rocuronium Bromide Vials (Feb. 05 2020)

Availability of Gastrogel Antacid® Oral Suspension (Feb. 05 2020)

Availability of Integrilin® (Feb. 05 2020)

Availability of Tamoxifen Tablets (Feb. 04 2020)

Availability of Ferro-Grad C® Tablets (Feb. 04 2020)

Availability of Minims® Phenylephrine Eye Drops (Feb. 04 2020)

Availability of Panadol® Suppositories (Feb. 04 2020)

Discontinuation of Zantac® Effervescent (Feb. 03 2020)

December 2018